This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Cablivi (caplacizumab)
General Description:
Cablivi (caplacizumab) is a medication approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP). It is a nanobody-based therapy designed to inhibit the interaction between von Willebrand factor (vWF) and platelets, thereby preventing excessive platelet aggregation and microthrombus formation in small blood vessels.
Cablivi is available as a powder or solution for injection and is used in combination with plasma exchange and immunosuppressive therapy. This combined approach helps to rapidly restore platelet counts and reduce the risk of disease recurrence.
Disease Indications:
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Manufacturer:
Ablynx NV (a Sanofi company)
Usage:
Intravenous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Therapeutic Goods Administration (TGA)
Package:
• Single-dose vial × 10 mg
Shipping:
Cold Chain Shipping
Cablivi contains temperature-sensitive active ingredients that are vulnerable to heat, light, and handling conditions. To maintain its stability and efficacy, the medicine is shipped under cold chain conditions, using specialized medical couriers equipped with temperature-controlled boxes and vehicles.
Although cold chain delivery can be more expensive than standard shipping, it ensures that Cablivi arrives uncompromised, potent, and ready for safe administration.
How to Access Cablivi (caplacizumab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Cablivi (caplacizumab) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
